Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:08:50.219Z.
Calculation as of: 2026-10-06T18:08:50.219Z.
Quote observation: 2026-10-06T18:05:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
PE RATIO
N/A
Market Cap
$868.65M
PE Ratio
N/A
TTM Avg
43.56
3Y Avg
43.56
5Y Avg
43.56
Market Cap
$860.07M
PE Ratio
2.85
TTM Avg
3.74
3Y Avg
21.90
5Y Avg
21.90
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $891.94M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $899.02M | 17.23 | 40.25 | 40.25 | 34.02 |
| HealthStream, Inc. (HSTM)vs › | $913.78M | 43.73 | 37.03 | 45.62 | 62.08 |
| Arbutus Biopharma Corp (ABUS)vs › | $877.52M | 5.69 | 5.80 | 5.80 | 5.80 |
| MoonLake Immunotherapeutics (MLTX)vs › | $927.47M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.06M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | N/A | 43.56 | 43.56 | 43.56 |
| Kura Oncology, Inc. (KURA)vs › | $939.11M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $860.07M | 2.85 | 3.74 | 21.90 | 21.90 |
| SI-BONE, Inc. (SIBN)vs › | $861.26M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$18.57
Forward EPS (Est.)
$-5.89
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
